You are here

  • Home
  • Archive
  • Volume 56, Issue 5
  • Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol

Article metrics

Article menu
Download PDFPDF
Therapeutics
Original article
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol

 

Online download statistics by month:

Online download statistics by month: December 2018 to March 2024

AbstractFullPdf
Dec 20182781210
Jan 2019117714857
Feb 20194205021
Mar 20193622616
Apr 20194073221
May 20193183325
Jun 20191091510
Jul 2019150109
Aug 201910097
Sep 2019951312
Oct 201912288
Nov 2019130710
Dec 20199052
Jan 202012886
Feb 20209832
Mar 20208710
Apr 202011297
May 202010067
Jun 202014156
Jul 20209165
Aug 202097134
Sep 202016777
Oct 202014577
Nov 20208952
Dec 20207344
Jan 20216866
Feb 2021135911
Mar 20217245
Apr 20217858
May 20211924
Jun 202112107
Jul 2021612
Aug 202114106
Sep 2021310
Oct 20217745
Nov 202178127
Dec 20217397
Jan 202212275
Feb 202219584
Mar 2022194154
Apr 202211308
May 202212343
Jun 202211340
Jul 20229192
Aug 20227263
Sep 202280105
Oct 202210153
Nov 20228662
Dec 20223943
Jan 20237984
Feb 202310920
Mar 202313884
Apr 20236742
May 202311031
Jun 20235620
Jul 202310664
Aug 20239131
Sep 20236010
Oct 20237733
Nov 20237511
Dec 202318223
Jan 202413774
Feb 20244735
Mar 202412583
Total8509654410